Cantor Fitzgerald Forecasts Ardelyx FY2025 Earnings

Ardelyx, Inc. (NASDAQ:ARDX) – Equities researchers at Cantor Fitzgerald issued their FY2025 EPS estimates for Ardelyx in a note issued to investors on Tuesday, March 4th. Cantor Fitzgerald analyst P. Agrawal expects that the biopharmaceutical company will post earnings of ($0.13) per share for the year. Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for Ardelyx’s current full-year earnings is ($0.18) per share.

ARDX has been the topic of a number of other reports. Piper Sandler lifted their price target on shares of Ardelyx from $7.00 to $8.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Raymond James reissued a “strong-buy” rating and set a $13.00 target price (down from $15.00) on shares of Ardelyx in a research report on Friday, February 21st. BTIG Research began coverage on shares of Ardelyx in a research report on Tuesday. They set a “buy” rating and a $14.00 target price on the stock. HC Wainwright reissued a “neutral” rating and set a $5.50 target price on shares of Ardelyx in a research report on Friday, February 21st. Finally, Scotiabank began coverage on shares of Ardelyx in a research report on Friday. They set a “sector outperform” rating and a $15.00 target price on the stock. Three analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.95.

Ardelyx Trading Down 0.4 %

Shares of ARDX stock opened at $5.30 on Thursday. The stock has a market cap of $1.26 billion, a price-to-earnings ratio of -33.13 and a beta of 0.85. The company has a quick ratio of 4.31, a current ratio of 4.58 and a debt-to-equity ratio of 0.87. Ardelyx has a fifty-two week low of $4.32 and a fifty-two week high of $9.33. The firm’s 50 day moving average price is $5.39 and its two-hundred day moving average price is $5.60.

Ardelyx (NASDAQ:ARDX) last announced its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.02. The firm had revenue of $116.13 million for the quarter, compared to analysts’ expectations of $111.16 million. Ardelyx had a negative net margin of 11.73% and a negative return on equity of 24.87%.

Institutional Trading of Ardelyx

Institutional investors have recently added to or reduced their stakes in the business. Wealth Enhancement Advisory Services LLC grew its position in Ardelyx by 34.3% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 28,365 shares of the biopharmaceutical company’s stock valued at $195,000 after buying an additional 7,245 shares in the last quarter. Tyler Stone Wealth Management grew its position in Ardelyx by 87.0% in the 3rd quarter. Tyler Stone Wealth Management now owns 96,850 shares of the biopharmaceutical company’s stock valued at $667,000 after buying an additional 45,055 shares in the last quarter. Los Angeles Capital Management LLC grew its position in Ardelyx by 51.8% in the 3rd quarter. Los Angeles Capital Management LLC now owns 170,544 shares of the biopharmaceutical company’s stock valued at $1,175,000 after buying an additional 58,219 shares in the last quarter. Aigen Investment Management LP grew its position in Ardelyx by 29.4% in the 3rd quarter. Aigen Investment Management LP now owns 23,510 shares of the biopharmaceutical company’s stock valued at $162,000 after buying an additional 5,346 shares in the last quarter. Finally, Simplify Asset Management Inc. lifted its holdings in Ardelyx by 15.3% in the 3rd quarter. Simplify Asset Management Inc. now owns 689,364 shares of the biopharmaceutical company’s stock valued at $4,750,000 after acquiring an additional 91,364 shares during the last quarter. Institutional investors own 58.92% of the company’s stock.

Insider Activity at Ardelyx

In other Ardelyx news, CEO Michael Raab sold 25,000 shares of the business’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $5.26, for a total transaction of $131,500.00. Following the completion of the sale, the chief executive officer now owns 1,150,385 shares in the company, valued at $6,051,025.10. The trade was a 2.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director David M. Mott bought 213,300 shares of the stock in a transaction on Thursday, December 19th. The shares were acquired at an average price of $4.67 per share, with a total value of $996,111.00. Following the purchase, the director now owns 1,638,765 shares of the company’s stock, valued at $7,653,032.55. The trade was a 14.96 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 490,029 shares of company stock valued at $2,377,766 and have sold 183,076 shares valued at $985,304. 5.90% of the stock is currently owned by corporate insiders.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.